# APIMEDS PHARMACEUTICALS US, INC. (APUS) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1894525 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/APUS) · [JSON](https://www.pops4.com/boards/company/APUS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026037575/0001213900-26-037575-index.htm))
- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-04-22 ([filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/0001213900-26-046671-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026057713/0001213900-26-057713-index.htm))
- Item 5.02 Director or officer change: 10, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026105484/0001213900-26-105484-index.htm))

## Recent filings

- 8-K · filed 2026-10-13 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026108780/0001213900-26-108780-index.htm)
- 8-K · filed 2026-10-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026105484/0001213900-26-105484-index.htm)
- 8-K · filed 2026-09-29 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026104668/0001213900-26-104668-index.htm)
- 8-K · filed 2026-09-23 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026102321/0001213900-26-102321-index.htm)
- 8-K · filed 2026-09-11 · 1.01 Entry into a Material Definitive Agreement; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026099002/0001213900-26-099002-index.htm)
- 8-K · filed 2026-08-21 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/0001213900-26-092680-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001894525.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1894525

## Cite

POPS4, Edgar & Edgarette: APIMEDS PHARMACEUTICALS US, INC. (APUS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/APUS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.